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Background: Vascular access thrombosis increases morbidity in hemodialysis (HD) patients. The aim of this
study was to investigate the association between HD vascular access thrombosis and mutations in the
prothrombin and factor V Leiden (FV) genes and ABO blood system.
Methods: This cross-sectional study included 195 patients with end stage renal disease (ESRD) on HD formore
than six months. HD patients were allocated into two groups according to the occurrence (cases, N=46) or
not (controls, N=149) of previous vascular access thrombosis. FV and prothrombin gene mutations were
investigated by polymerase chain reaction and ABO blood group phenotyping was performed by the indirect
technique. Univariate analysis detected the variables with a trend to be associated with thrombosis and was
followed by multivariate analysis to deﬁne independent predictors of vascular access thrombosis.
Results: FV Leiden mutation and ABO blood group were not associated with vascular access thrombosis,
whereas G20210Amutation in the prothrombin gene was signiﬁcantly higher in patients with vascular access
thrombosis and independently associated with this complication (OR=12.0; CI 95%=1.8–83.5; p=0.012).
Conclusions: G20210A mutation emerges as an important genetic factor predisposing to vascular access
thrombosis. The deﬁnition of risk factors for thrombosis will certainly enable a rational approach for HD
patients.
© 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Hemodialysis (HD) requires a well-functioning vascular access
that allows sufﬁcient blood ﬂow to achieve adequate clearance and
blood dialysis. Vascular access complications increase morbidity and
contribute to 20–25% of all hospitalizations in dialysis patients, of
which approximately 85% of cases is due to thrombosis [1,2].
ESRD as well as HD itself may actually increase the risk of throm-
bosis. Among other factors, the increasing thrombotic trend in
patients under HD is due to platelets and clotting factors activation
[3–5]. It is believed that almost all cases of thrombotic episodes in HD
patients are associated to a reduction in vascular access blood ﬂow
due to ﬁbromuscular and intimal hyperplasia, which may result in
vascular access stenosis. The blood ﬂow reduction causes blood stasis
and favors hypercoagulability, hypotension and hypovolemia, predis-
posing to a prothrombotic environment [6,7]. Although thrombotic
episodes are primarily related to mechanical or surgical events, thexicological Analysis, Faculty of
P: 31270-901, Belo Horizonte/
3409 6985.
se).
vier OA license.genetic background of the patient may also signiﬁcantly contribute to
the occurrence of vascular access thrombosis. In this context, it should
be highlighted that some patients with very similar risk factors for
thrombosis relative to HD procedure do not experience vascular
access thrombosis, whereas others do.
Thrombophilia results from either inherited or acquired factors,
which predispose to thrombosis [8] and it has been proposed as a
possible cause of the vascular access thrombosis [9–11]. Among the
mutations associated with thromboembolism, mutations in the factor
V (FV) and prothrombin genes have been reported as the most
frequent genetic determinants [12,13]. Resistance to activated protein
C (APC) is regarded as an important coagulation abnormality asso-
ciated with venous thrombosis. Most of the cases of APC resistance
results of a missensemutation induced by the replacement of guanine
by adenine at nucleotide 1691 in exon 10 of the FV gene (G1691A)-
rs6025, known as FV Leiden. The resulting point mutation at
nucleotide 1691 causes the replacement of arginine to glutamine at
amino acid 506, located at one of the sites where FV is recognized,
cleaved, and inactivated by the APC. In consequence, FVa is not
enough inactivated, which in turn predisposes thrombosis [14].
The replacement of guanine by adenine at nucleotide 20210 in the 3′
untranslated region of the prothrombin gene (G20210A)-rs1799963,
426 D.R.A. Rios et al. / Clinica Chimica Acta 412 (2011) 425–429before poli(A) tail ﬁxation site, is another common molecular
determinant of inherited thromboembolism. This alteration increases
the messenger RNA stability, resulting in elevated prothrombin plasma
levels that leads to higher thrombin production and, consequently,
increased conversion of ﬁbrinogen into ﬁbrin [12].
Beyond these inherited factors, studies have also demonstrated
association between ABO blood system and venous thromboembolism
(VTE), indicating that individuals of “non O” blood groups (A, B or AB
groups) present an increased VTE risk as compared to O blood group
carriers [15–18]. The “non O” blood group patients exhibit higher
plasma levels of factor VIII (FVIII) [19,20] and von Willebrand factor
(vWF) [19–21] than those belonging to blood group O. Moreover, it has
been hypothesized that oligosaccharides in vWF are similar to those
present in antigens that correspond to blood groups A and B. The
presence of these structures may affect the clearance of both vWF and
vWF/FVIII complex [21,22], probably by altering the proteolysis of both
vWF by the metalloprotease ADAMTS13 [23]. To our knowledge, no
previous study in the literature has evaluated the association between
ABO blood group and the risk of vascular access thrombosis. Based on
the fact that mutations may differ signiﬁcantly among ethnic groups,
this is the ﬁrst study in Brazilian population with the aim to investigate
the association between hemodialysis vascular access thrombosis and
the three thrombophilic disorders (mutations in the prothrombin and
FV genes and ABO blood system).
2. Subjects and methods
2.1. Study design
The present cross-sectional study included all prevalent patients
(N=195) with ESRD undergoing HD therapy for more than six
months at two dialysis centers in Belo Horizonte/MG, Brazil from 2007
to 2009, according to the exclusion and inclusion criteria.
2.2. Ethical aspects
The Ethics Committee of our institution approved the study and
informed consent was obtained from all participants. The research
protocol did not interfere with any medical recommendations or
prescriptions.
2.3. Exclusion criteria
Patients receiving oral anticoagulation therapy or oral contra-
ceptives, with prior history of arterial or venous thrombosis, except
those with vascular access thrombosis, with acute or chronic hepatic
disease, systemic lupus erythematosus, malignant diseases, vasculitis,
acute infections, history of renal transplantation, HIV positive and
pregnant women were automatically excluded from the study.
2.4. Inclusion criteria
We allocated HD patients with arteriovenous ﬁstula (AVF) into
two groups according to the occurrence or not of previous episode of
vascular access thrombosis. The case group consisted of 46 patients
whose functioning dialysis access had, at least, one previous episode
of thrombotic occlusion, which was deﬁned by the absence of blood
ﬂow and the impossibility to use the access for dialysis. The remaining
149 patients have not experienced this disturbance and were enrolled
as control group.
2.5. Study protocol
All patients required regular HD sessions for 3 to 4 h, three times a
week. Blood ﬂow was usually 300–450 mL/min with a dialysate ﬂow
at a constant rate of 500 mL/min. Patients were dialyzed either withlow-ﬂux polysulphone membranes and high-ﬂow polysulphone
membranes with bicarbonate-buffered dialysate. All patients received
regular doses of standard heparin (100 to 150 UI/kg) before hemo-
dialysis session. A detailed history, clinical variables (age, gender, BMI,
pre-dialysis blood pressure levels, etiology of ESRD, presence of
diabetes or not, type of vascular access, time on hemodialysis, inter-
dialytic weight gain, and main medications in use) and dialysis
parameters (urea reduction ratio and normal protein catabolism rate)
of each included patient were recorded in a computer speciﬁc data
bank.
After informed consent, all patients were submitted to blood
collection for the determination of ABO group phenotype and the
evaluation of mutations in FV and prothrombin genes.
2.6. Blood sampling
Blood samples were drawn in sodium citrate (0.129 mol/L) in 9:1
volume ratio and in EDTA from HD vascular access prior dialysis
procedure in the ﬁrst dialysis session of the week. Citrated blood
samples were centrifuged at 2500 g for 20 min at 4 °C to obtain
plasma. The blood samples collected in EDTA tubes were submitted to
genomic DNA extraction using the Wizard Genomic DNA Puriﬁcation
(Promega®). Samples were aliquoted and stored at −70 °C until
analysis.
2.7. FV and prothrombin genes mutations
Mutations were investigated by polymerase chain reaction (PCR-
RFLP) using oligonucleotides, restriction endonucleases and condi-
tions, as previously described [12,24]. Samples were analyzed by
silver stained polyacrylamide gel electrophoresis.
2.8. ABO group
ABO blood group phenotyping was performed by the indirect
technique using citrated plasma.
2.9. Statistical analysis
Statistical comparisons were performed using the program SIGMA
STAT (version 2.03) e STATA (version 10.0). Categorical variables
were compared using χ2 or Fisher's exact test, and continuous
variables were compared by t test or the Mann–Whitney U test, as
appropriate. It was investigated whether the mutations in the
prothrombin and FV genes and ABO blood group were associated
with vascular access thrombosis. The variables that showed a trend
toward statistical signiﬁcance with vascular access thrombosis on
univariate analysis (Pb0.2) and those considered confounding factors,
such as age, gender, BMI, time on hemodialysis and diabetes were
included in the multiple logistic regression model to identify inde-
pendent predictors of vascular access thrombosis. The multivariate-
adjusted odds ratio (OR) and their 95% conﬁdence intervals (95% CI)
were also calculated. Differences were considered signiﬁcant when
Pb0.05.
3. Results
Clinical variables and hemodialysis parameters of the patients did
not differ between cases and controls, as presented in Table 1. Age,
gender, BMI, pre-dialysis blood pressure levels, etiology of ESRD, pre-
sence of diabetes or not, type of vascular access, time on hemodialysis,
interdialytic weight gain, main medications in use and dialysis
parameters were similar in both groups (PN0.05 for all comparisons,
Table 1).
Among the 46 patients in the case group, four (8.7%) were hetero-
zygous for G20210Amutation in the prothrombin gene, and none had
Table 1
Clinical characteristics and dialysis parameters of hemodialysis patients with (cases)






Age (years) 52 (39–60) 50 (41–59) 0.979
Sex 0.100
Male [n(%)] 86 (58%) 20 (43%)
Female [n(%)] 63 (42%) 26 (57%)
BMI (kg/m2) 24.2±4.7 24.5±5.7 0.734
Cause of ESRD [n(%)]
Hypertensive nephrosclerosis 51 (34%) 14 (30%) 0.633
Glomerulopathies 39 (26%) 7 (15%) 0.126
Diabetic nephropathy 21 (14%) 12 (26%) 0.060
Polycystic kidney disease 7 (5%) 3 (7%) 0.624
Others or unknowns causes 31 (21%) 10 (22%) 0.892
Pre-dialysis arterial blood pressure
Systolic blood pressure (mmHg) 130 (120–143) 140 (130–150) 0.060
Diastolic blood pressure (mmHg) 80 (80–90) 80 (80–90) 0.968
Time on hemodialysis (months) 34.0 (17.0–90.3) 39.5 (19.0–92.0) 0.226
Type of vascular access 0.131
Arteriovenous ﬁstula 144 (97%) 42 (91%)
Arteriovenous graft 5 (3%) 4 (9%)
Kt/v 1.4 (1.3–1.6) 1.5 (1.3–1.6) 0.513
URR 73.6±5.9 74.0±6.4 0.716
nPCR (g/kg/day) 1.1 (1.0-1.4) 1.2 (1.0–1.6) 0.451
IWG (Kg) 3.2±1.1 2.9±1.4 0.165
Medications [n(%)]
Antihypertensive drugs
ACE inhibitor 69 (46%) 19 (41%) 0.551
β-blockers 64(43%) 21 (46%) 0.747
Calcium channel antagonists 65 (44%) 17 (37%) 0.423
Acetylsalicylic acid 38 (26%) 8 (17%) 0.257
Statins 31 (21%) 5 (11%) 0.129
Vitamin use 149 (100%) 46 (100%)
Insulin 29 (19%) 10 (22%) 0.736
Erythropoietin 129 (87%) 41 (89%) 0.651
Diabetes [n(%)] 40 (27%) 15 (33%) 0.448
*Pb0.05. The normally distributed data were expressed as mean±SD (t test). The non-
Gaussian data were presented as median (range). (Mann–Whitney test). Frequencies
(%) was evaluated by χ2 test. BMI: body mass index; HD: hemodialysis; URR: urea
reduction ratio; nPCR: normal protein catabolism rate; IWG: interdialytic weight gain;
ACE: angiotensin-converting enzyme.
Table 3
Frequency of blood ABO groups in hemodialysis patients with (cases) and without
(controls) previous episode of vascular access thrombosis.
Blood group Controls (n=149) Cases (n=46) P value
O 75 (50.3%) 23 (50.0%) 0.833
A 47 (31.6%) 13 (28.3%) 0.726
B 21 (14.1%) 7 (15.2%) 0.611
AB 6 (4.0%) 3 (6.5%) 0.381
“non O” 74 (49.7%) 23 (50%) 0.833
Table 4
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heterozygous for G20210A, and other two (1.3%) were heterozygous
for G1691A. None was homozygous for the both mutations (Table 2).
Regarding the ABO blood group distribution, in the case group, 23
(50.0%) were group O, 13 (28.3%) group A, 7 (15.2%) group B and 3
(6.5%) group AB. In the control group was observed 75 (50.3%)
participants belonged to group O, 47 (31.6%) to group A, 21 (14.1%) to
group B and 6 (4.0%) to group AB (Table 3). Patients from the A, B and
AB blood groups were pooled as “non O” and the ABO blood group
frequencies among two groups (O and “non O”) were not signiﬁcantly
different (P=0.833), as shown in Table 3.
FV Leidenmutation and ABO blood groupwere not associatedwith
vascular access thrombosis in the univariate analysis. On the other
hand, there was a signiﬁcantly higher frequency of G20210Amutation
in the prothrombin gene in patients with vascular access thrombosis
than in those who did not have this complication (OR: 7.0; CI 95%:
1.1–57.3; P=0.01). Despite not signiﬁcantly associated with vascularTable 2
Frequency of mutations in the prothrombin (G20210A) and factor V Leiden (G1691A)
genes in hemodialysis patients with (cases) and without (controls) previous episode of
vascular access thrombosis.
Mutation Genotype Controls (n=149) Cases (n=46)
G20210A Heterozygous 2 (1.3%) 4 (8.7%)
Negative 147 (98.7%) 42 (91.3%)
G1691A Heterozygous 2 (1.3%) 0 (0%)
Negative 147 (98.7%) 46 (100%)access thrombosis in univariate model, patients with lower pre-
dialysis systolic pressure levels and higher interdialytic weight gain
exhibited a trend to vascular access thrombosis (Pb0.20). Therefore,
these variables were included in the multiple logistic regression
model along with the presence of G20210A mutation in the
prothrombin gene and confounding factors (age, gender, BMI,
diabetes and time on hemodialysis). After adjusting, only the
prothrombin mutation (G20210A) had a signiﬁcant and indepen-
dent association with vascular access thrombosis (OR: 12.0; CI 95%:
1.8–83.5; P=0.012). Indeed, the presence of G20210A mutation in
the prothrombin gene increased 12 fold the chance of vascular access
thrombosis in HD patients (Table 4).
4. Discussion
The present study was proposed to investigate the possible role of
G20210A mutation, FV Leiden and ABO phenotype in predisposing
vascular access thrombosis. After adjusting for relevant clinical
variables (age, gender, BMI, time on hemodialysis and diabetes)
statistical analysis has shown that only the G20210A mutation in the
prothrombin gene was independently associated to an increased risk
for vascular access thrombosis (OR: 12.0; CI 95%: 1.8–83.5; P=0.012).
This mutation has been identiﬁed as one of the main risk factors for
thrombosis development, especially deep venous thrombosis. In this
study, four patients (8.7%) in the case group and two (1.3%) in the
control group were detected as heterozygous for G20210A. The
reduced number of G20210A carriers found in our study may reﬂect
the low frequency of this mutation in Brazilian population. In a
previous study, our group detected a frequency of 1.3% among
Brazilian subjects with no previous history of thrombosis [18].
In agreement with the present study, Ataç et al. [9] detected 4 (9%)
heterozygous for G20210A among 46 patients under HD with vascular
access thrombosis, whereas the mutation was not identiﬁed in 44
patients without this complication, suggesting that the G20210A
mutation may in fact contribute to vascular access thrombosis. In
contrast, other studies did not ﬁnd a signiﬁcant association between the
presence of G20210A and vascular access thrombosis [10,11,25–27].
FVL constitutes the genetic alteration more frequently associated
to venous thrombosis in Caucasian populations by increasing 6.6
times the risk for this event. Although, the association between FV
Leiden and arterial thrombosis is still controversial [13] in BrazilianOdds ratio, conﬁdence interval (95% CI) and p value of the multiple logistic regression
model considering the vascular access thrombosis as the response variable.
Variables Odds ratio CI 95% P value
Age 0.99 0.97–1.10 0.986
Gender 0.50 0.99–1.00 0.083
BMI 0.97 0.89–1.10 0.501
Time on hemodialysis (months) 1.00 0.99–1.00 0.702
IWG 0.99 0.99–1.00 0.467
Systolic blood pressure 1.02 0.99–1.14 0.080
Diabetes 1.08 0.43–2.72 0.874
G20210A mutation 12.0 1.81–83.5 0.012*
*Pb0,05. BMI: body mass index; IWG: interdialytic weight gain.
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study, only two patients were heterozygous for FV Leiden in the
control group and none in the case group, suggesting that this muta-
tion is not associated to thrombotic complications in the vascular
access. This ﬁnding is consonant with other studies that did not also
observed association between FV Leiden and vascular access throm-
bosis [25,27,29,30]. On the other hand, the association between FV
Leiden mutation and vascular access thrombosis was previously
reported for patients undergoing HD [9–11]. Therefore, larger series of
patients are still required to conﬁrm this association, considering the
limited sample size and the reduced number of participants with this
mutation in this study.
The conﬂicting results obtained in different studies on the association
between both G20210A and FVL and vascular access thrombosis may be
explained, at least in part, by ethnic differences of the populations, the
inadequate control of other risk factors for thrombosis, as well as the
limited sample size assayed in the different studies. The ethnic origin of
participants was not considered in the present study, since the Brazilian
population is one of the most heterogeneous around the world. This
aspect certainly impairs the deﬁnition of ethnic origin of the participants
of this study based on phenotypic characteristics only [31].
In general, the blood groups distribution for the participants of this
study was similar to that obtained for blood donators from the same
region, with a higher frequency for group O, followed by groups A, B
and AB [32]. The classiﬁcation of controls and cases into groups O and
“non O” (groups A, B and AB included) showed a very similar fre-
quency for both (Table 3). The literature suggests that “non O”
subjects have shown an increased predisposition to thrombotic
events [15–18]. However, in the present study, this ﬁnding was not
conﬁrmed, indicating that this factor seems to be not important in
predisposing vascular access thrombosis in HD patients.
In spite of the limited number of participants enrolled in this study,
our preliminary results suggest that G20210A mutation may be an
important genetic factor predisposing to vascular access thrombosis
[9]. Hemodialysis per se leads to a number of hemostatic alterations
that contribute to a hypercoagulability state in HD patients.
Furthermore, ﬁstula surface promotes platelet and ﬁbrinogen adhe-
sion [33], leading to a prothrombotic microenvironment that favors
clot formation. Knowing that hyperprothrombinemia is the pheno-
type associated to G20210Amutation, it is reasonable to suppose that,
in patients with an already compromised hemostatic system, the
increased prothombin plasma levels and consequent thrombin
generation may culminate with thrombosis at vascular access.
Although the frequency of G20210A mutation in Brazilian general
population is lower than that observed for the majority of the
European countries [34], in Brazilian patients with venous and arterial
thrombosis this mutation has been associated to increased risk for
these pathologies, reaching frequencies near 5% in some studies [35].
Our group has observed that G20210A mutation is associated to
increased risk of venous thrombosis in young Brazilian patients (OR:
3.36; CI 95%: 1.15–9.84; P=0.027) [18]. Therefore, is reasonable to
expect that presence of G20210A may additionally contribute to
trigger the blood clot especially on the ﬁstula surface, since multiple
factors interact leading to thromboembolic events and that a
hypercoagulability state is usually found in HD patients.
Taken together our data allow us to suggest that the investigation
of G20210A mutation may be important on the thrombotic risk
assessment in the HD patients, mainly in those presenting a
hypercoagulability state due to diabetes, hypertension and other
diseases. Moreover, regardless the limitations of this study, to our
knowledge, this is the ﬁrst time that the possible association between
blood group ABO and thrombotic vascular access is investigated, thus
contributing for a better understanding of risk factors enrolled in this
condition. The deﬁnition of risk factors for thrombosis will certainly
enable a rational approach of patients under HD regarding the pre-
scription of oral anticoagulants and/or platelets antiagregants.Acknowledgements
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